
UK - LondonTechnology Fund backs vaccines for viruses technology
London Technology Fund (LTF) has completed an investment in Immune Targeting Systems (ITS) Ltd, a company which is developing vaccines for mutating viruses. LTF is participating in a £3.5m series-A funding round for ITS alongside Novartis Venture Fund (Switzerland), HealthCap (Sweden) and Truffle Capital (France). The London Development Agency will also be contributing an Exceptional Development Project award of £500,000 under the Grant for Research and Development scheme. As a result of the investment the company has been able to recruit its core team of development scientists and will move into dedicated facilities at the London BioScience Innovation Centre.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater